We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+6.32%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.2B
AUM Growth
+$1.75B
Cap. Flow
+$1.1B
Cap. Flow %
6.8%
Top 10 Hldgs %
54.17%
Holding
115
New
28
Increased
36
Reduced
22
Closed
20

Top Buys

Rank Stock Value
1
AABA
Altaba Inc
AABA
+$784M
2
ESRX
Express Scripts Holding Company
ESRX
+$504M
3
GD icon
General Dynamics
GD
+$348M
4
XL
XL Group Ltd.
XL
+$329M
5
KDP icon
Keurig Dr Pepper
KDP
+$194M

Top Sells

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$618M
2
MON
Monsanto Co
MON
+$543M
3
COL
Rockwell Collins
COL
+$151M
4
ABLX
Ablynx NV
ABLX
+$134M
5
PPLI
People Inc
PPLI
+$112M

Sector Composition

Rank Sector Weight
1 Healthcare 20.57%
2 Technology 19.02%
3 Financials 14.39%
4 Communication Services 11.79%
5 Industrials 10.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
76
Zymeworks
ZYME
$2.05B
$11.2M 0.07%
+755,000
New +$11.7M
TECX
77
Tectonic Therapeutic
TECX
$736M
$10.1M 0.06%
+29,450
New +$10.6M
IMMU
78
DELISTED
Immunomedics Inc
IMMU
$9.47M 0.06%
+400,000
New +$8.04M
PF
79
DELISTED
Pinnacle Foods, Inc.
PF
$9.43M 0.06%
+145,000
New +$8.93M
VOYA icon
80
Voya Financial
VOYA
$8.86B
$8.7M 0.05%
185,000
– –
AKRX
81
DELISTED
Akorn Inc
AKRX
$7.3M 0.05%
+440,000
New +$6.75M
SYBX
82
DELISTED
Synlogic
SYBX
$6.73M 0.04%
45,671
-19,329
-30% -$3.1M
PTGX icon
83
Protagonist Therapeutics
PTGX
$9.99B
$6.12M 0.04%
910,229
-103,271
-10% -$793K
TBIO
84
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5.06M 0.03%
+400,000
New +$4.83M
GCVRZ
85
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.41M 0.02%
6,827,805
– –
PFNX
86
DELISTED
Pfenex Inc.
PFNX
$3.25M 0.02%
+600,000
New +$3.47M
XERS icon
87
Xeris Biopharma Holdings
XERS
$1.59B
$3.03M 0.02%
+159,500
New +$3.1M
TYME
88
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$3M 0.02%
948,390
-481,899
-34% -$1.37M
VEON icon
89
VEON
VEON
$4.09B
$2.38M 0.01%
40,000
-580,040
-94% -$36.3M
MOR
90
DELISTED
MorphoSys AG American Depositary Shares
MOR
$2.17M 0.01%
+71,631
New +$1.97M
KNSA icon
91
Kiniksa Pharmaceuticals
KNSA
$6.17B
$1.99M 0.01%
+114,589
New +$2.07M
SURF
92
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.63M 0.01%
+100,000
New +$1.45M
KZR
93
DELISTED
Kezar Life Sciences
KZR
$1.33M 0.01%
+7,667
New +$1.34M
SPPI
94
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1.05M 0.01%
+50,000
New +$926K
BG icon
95
Bunge Global
BG
$21.7B
– –
-690,000
Closed -$51M
LKFT
96
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
– –
-308,260
Closed -$30.8M
CBIO
97
Crescent Biopharma
CBIO
$637M
– –
-2,500
Closed -$4.06M
HAIN icon
98
Hain Celestial
HAIN
$71.6M
– –
-545,000
Closed -$17.5M
PPLI
99
People Inc
PPLI
$2.86B
– –
-4,000,716
Closed -$112M
QCOM icon
100
Qualcomm
QCOM
$169B
– –
-960,000
Closed -$53.2M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2018 Portfolio in Review

As of Q2 2018, Thomas Steyer held 115 positions worth $16.2B, up 12% from $14.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Thomas Steyer deployed $1.1B of net new capital in Q2 2018, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was General Dynamics: 1,697,715 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 16% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was NXP Semiconductors, an estimated $618M trimmed.

  • Thomas Steyer's largest Q2 2018 buy was General Dynamics: 1,697,715 shares worth $316M.
  • Thomas Steyer added most to Altaba Inc in Q2 2018, an estimated $784M increase.
  • Thomas Steyer's biggest Q2 2018 reduction was NXP Semiconductors, cutting an estimated $618M.
  • Thomas Steyer fully exited Monsanto Co in Q2 2018, selling an estimated $543M.
  • Thomas Steyer's ten largest holdings make up 54% of its $16.2B portfolio in Q2 2018.
  • Thomas Steyer opened 28 new positions and closed 20 in Q2 2018.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $16.2B.

Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.